{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:17:40Z","timestamp":1791249460101,"version":"4.1.0"},"reference-count":363,"publisher":"Impact Journals, LLC","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,9,19]]},"DOI":"10.18632\/oncotarget.19531","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T09:42:26Z","timestamp":1500975746000},"page":"71249-71284","source":"Crossref","is-referenced-by-count":172,"title":["Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy"],"prefix":"10.18632","volume":"8","author":[{"given":"Ruan F.V.","family":"Medrano","sequence":"first","affiliation":[{"name":"Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of S\u00e3o Paulo\/LIM 24, University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Hunger","sequence":"additional","affiliation":[{"name":"Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of S\u00e3o Paulo\/LIM 24, University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir Andrade","family":"Mendon\u00e7a","sequence":"additional","affiliation":[{"name":"Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of S\u00e3o Paulo\/LIM 24, University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alexandre M.","family":"Barbuto","sequence":"additional","affiliation":[{"name":"Department of Immunology, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"},{"name":"Cell and Molecular Therapy Center, NUCEL-NETCEM, University of S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan E.","family":"Strauss","sequence":"additional","affiliation":[{"name":"Viral Vector Laboratory, Center for Translational Investigation in Oncology, Cancer Institute of S\u00e3o Paulo\/LIM 24, University of S\u00e3o Paulo School of Medicine, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Lindenmann","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12026-012-8293-7","article-title":"Activation and regulation of interferon-\u03b2 in immune responses","volume":"53","author":"Chin","year":"2012","journal-title":"Immunol Res"},{"key":"3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Walter","year":"2004","journal-title":"Immunol Rev"},{"key":"5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Kroemer","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni1213","article-title":"A critical function for type I interferons in cancer immunoediting","volume":"6","author":"Schreiber","year":"2005","journal-title":"Nat Immunol"},{"key":"7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Schreiber","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Smyth","year":"2011","journal-title":"Science"},{"key":"9","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Schreiber","year":"2011","journal-title":"J Exp Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","article-title":"Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution","volume":"137","author":"Cohn","year":"1973","journal-title":"J Exp Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.149.1.1","article-title":"Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance","volume":"149","author":"Cohn","year":"1979","journal-title":"J Exp Med"},{"key":"12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Mellman","year":"2013","journal-title":"Immunity"},{"key":"13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nri1996","article-title":"Steady-state and inflammatory dendritic-cell development","volume":"7","author":"Naik","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coi.2017.01.002","article-title":"Dendritic cells in cancer: the role revisited","volume":"45","author":"Gabrilovich","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic Cells and Cancer Immunity","volume":"37","author":"Ruffell","year":"2016","journal-title":"Trends Immunol"},{"key":"16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Kirkwood","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Yona","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.immuni.2016.10.010","article-title":"Functions of Murine Dendritic Cells","volume":"45","author":"Murphy","year":"2016","journal-title":"Immunity"},{"key":"19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-immunol-032713-120204","article-title":"Transcriptional Control of Dendritic Cell Development","volume":"34","author":"Murphy","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Murphy","year":"2008","journal-title":"Science"},{"key":"21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition","volume":"44","author":"Hogstad","year":"2016","journal-title":"Immunity"},{"key":"22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20092618","article-title":"Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells","volume":"207","author":"Donckier","year":"2010","journal-title":"J Exp Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1158\/2326-6066.CIR-14-0165","article-title":"Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B, GM-CSF: Recruitment and Activation of BDCA3\/CD141(+) Dendritic Cells and Enhanced Cross-Presentation","volume":"3","author":"de Gruijl","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical Role for CD103(+)\/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma","volume":"30","author":"Krummel","year":"2016","journal-title":"Cancer Cell"},{"key":"25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10875-009-9284-x","article-title":"Molecular characterization of human plasmacytoid dendritic cells","volume":"29","author":"Cao","year":"2009","journal-title":"J Clin Immunol"},{"key":"26","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1084\/jem.20060401","article-title":"Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation","volume":"203","author":"Barrat","year":"2006","journal-title":"J Exp Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1189\/jlb.0411190","article-title":"Plasmacytoid dendritic cells and cancer","volume":"90","author":"Facchetti","year":"2011","journal-title":"J Leukoc Biol"},{"key":"28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.it.2010.05.004","article-title":"Trafficking properties of plasmacytoid dendritic cells in health and disease","volume":"31","author":"Facchetti","year":"2010","journal-title":"Trends Immunol"},{"key":"29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/11360","article-title":"Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon","volume":"5","author":"Colonna","year":"1999","journal-title":"Nat Med"},{"key":"30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2016.05.008","article-title":"Plasmacytoid dendritic cell role in cutaneous malignancies","volume":"83","author":"Abbas","year":"2016","journal-title":"J Dermatol Sci"},{"key":"31","first-page":"6478","article-title":"Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer","volume":"63","author":"Hartmann","year":"2003","journal-title":"Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-12-3058","article-title":"Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment","volume":"73","author":"Caux","year":"2013","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","article-title":"Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells","volume":"234","author":"Bover","year":"2010","journal-title":"Immunol Rev"},{"key":"34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.it.2013.06.001","article-title":"Inflammatory dendritic cells in mice and humans","volume":"34","author":"Amigorena","year":"2013","journal-title":"Trends Immunol"},{"key":"35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Gabrilovich","year":"2016","journal-title":"Trends Immunol"},{"key":"36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Sperling","year":"2014","journal-title":"Cancer Cell"},{"key":"37","article-title":"Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies","author":"Laoui","year":"2017","journal-title":"J Leukoc Biol"},{"key":"38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ccr.2012.01.008","article-title":"Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells","volume":"21","author":"Krummel","year":"2012","journal-title":"Cancer Cell"},{"key":"39","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.4161\/onci.22660","article-title":"Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models","volume":"1","author":"Janssen","year":"2012","journal-title":"OncoImmunology"},{"key":"40","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4049\/jimmunol.1403134","article-title":"Tumor-infiltrating dendritic cells in cancer pathogenesis","volume":"194","author":"Knutson","year":"2015","journal-title":"J Immunol"},{"key":"41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses","volume":"169","author":"Kim-Shulze","year":"2017","journal-title":"Cell"},{"key":"42","first-page":"71","article-title":"The receptor of the type I interferon family","volume":"316","author":"Pellegrini","year":"2007","journal-title":"Curr Top Microbiol Immunol"},{"key":"43","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1006\/geno.1994.1427","article-title":"Structure of the human type-I interferon gene cluster determined from a YAC clone contig","volume":"22","author":"Olopade","year":"1994","journal-title":"Genomics"},{"key":"44","article-title":"The human interferon-alpha species and hybrid proteins","volume":"24","author":"Pestka","year":"1997","journal-title":"Semin Oncol"},{"key":"45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF02678218","article-title":"Structure-activity of type I interferons","volume":"10","author":"Viscomi","year":"1997","journal-title":"Biotherapy"},{"key":"46","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1128\/MCB.01808-08","article-title":"Receptor density is key to the alpha2\/beta interferon differential activities","volume":"29","author":"Pellegrini","year":"2009","journal-title":"Mol Cell Biol"},{"key":"47","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1128\/MCB.26.5.1888-1897.2006","article-title":"Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta","volume":"26","author":"Schreiber","year":"2006","journal-title":"Mol Cell Biol"},{"key":"48","doi-asserted-by":"crossref","first-page":"32925","DOI":"10.1074\/jbc.M806019200","article-title":"The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities","volume":"283","author":"Schreiber","year":"2008","journal-title":"J Biol Chem"},{"key":"49","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1529\/biophysj.104.055855","article-title":"Lateral ligand-receptor interactions on membranes probed by simultaneous fluorescence-interference detection","volume":"88","author":"Piehler","year":"2005","journal-title":"Biophys J"},{"key":"50","doi-asserted-by":"crossref","first-page":"23630","DOI":"10.1074\/jbc.271.39.23630","article-title":"Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor","volume":"271","author":"Colamonici","year":"1996","journal-title":"J Biol Chem"},{"key":"51","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1128\/MCB.15.8.4208","article-title":"Ligand-induced association of the type I interferon receptor components","volume":"15","author":"Rubinstein","year":"1995","journal-title":"Mol Cell Biol"},{"key":"52","doi-asserted-by":"crossref","first-page":"26388","DOI":"10.1074\/jbc.272.42.26388","article-title":"A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state","volume":"272","author":"Colamonici","year":"1997","journal-title":"J Biol Chem"},{"key":"53","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cytogfr.2007.06.013","article-title":"How cells respond to interferons revisited: from early history to current complexity","volume":"18","author":"Stark","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"54","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1016\/S0021-9258(17)41893-X","article-title":"p135tyk2, an interferon-alpha-activated tyrosine kinase, is physically associated with an interferon-alpha receptor","volume":"269","author":"Krolewski","year":"1994","journal-title":"J Biol Chem"},{"key":"55","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/emboj\/cdg038","article-title":"The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression","volume":"22","author":"Pellegrini","year":"2003","journal-title":"EMBO J"},{"key":"56","doi-asserted-by":"crossref","first-page":"11839","DOI":"10.1073\/pnas.94.22.11839","article-title":"The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha\/beta receptor","volume":"94","author":"Pellegrini","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"57","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.1496401","article-title":"Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor","volume":"257","author":"Darnell","year":"1992","journal-title":"Science"},{"key":"58","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0092-8674(94)90357-3","article-title":"Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions","volume":"76","author":"Darnell","year":"1994","journal-title":"Cell"},{"key":"59","doi-asserted-by":"crossref","first-page":"30073","DOI":"10.1074\/jbc.273.46.30073","article-title":"Role of the STAT1-SH2 domain and STAT2 in the activation and nuclear translocation of STAT1","volume":"273","author":"David","year":"1998","journal-title":"J Biol Chem"},{"key":"60","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1101\/gad.3.9.1362","article-title":"Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted","volume":"3","author":"Darnell","year":"1989","journal-title":"Genes Dev"},{"key":"61","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/j.1460-2075.1990.tb08216.x","article-title":"Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3","volume":"9","author":"Darnell","year":"1990","journal-title":"EMBO J"},{"key":"62","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nri1900","article-title":"IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors","volume":"6","author":"Taniguchi","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"63","doi-asserted-by":"crossref","first-page":"8483","DOI":"10.1016\/S0021-9258(18)47439-X","article-title":"The human interferon-gamma receptor. Purification, characterization, and preparation of antibodies","volume":"262","author":"Rubinstein","year":"1987","journal-title":"J Biol Chem"},{"key":"64","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.immuni.2006.08.009","article-title":"Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors","volume":"25","author":"Taniguchi","year":"2006","journal-title":"Immunity"},{"key":"65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12101","article-title":"Interferon induction and function at the mucosal surface","volume":"255","author":"Durbin","year":"2013","journal-title":"Immunol Rev"},{"key":"66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.immuni.2006.08.014","article-title":"Complex modulation of cell type-specific signaling in response to type I interferons","volume":"25","author":"Stark","year":"2006","journal-title":"Immunity"},{"key":"67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature14554","article-title":"Corrigendum: A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"525","author":"Rice","year":"2015","journal-title":"Nature"},{"key":"68","first-page":"D1040","article-title":"Interferome v2.0: an updated database of annotated interferon-regulated genes","volume":"41","author":"Hertzog","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"69","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2006.11.053","article-title":"Differential receptor subunit affinities of type I interferons govern differential signal activation","volume":"366","author":"Piehler","year":"2007","journal-title":"J Mol Biol"},{"key":"70","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/imr.12001","article-title":"Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation","volume":"250","author":"Schreiber","year":"2012","journal-title":"Immunol Rev"},{"key":"71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ijc.20236","article-title":"Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors","volume":"111","author":"Croze","year":"2004","journal-title":"Int J Cancer"},{"key":"72","doi-asserted-by":"crossref","first-page":"13165","DOI":"10.1073\/pnas.95.22.13165","article-title":"Interaction affinity between cytokine receptor components on the cell surface","volume":"95","author":"Burkly","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"73","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0968-0004(98)01236-5","article-title":"The INK4a\/ARF tumor suppressor: one gene\u2014two products\u2014two pathways","volume":"23","author":"DePinho","year":"1998","journal-title":"Trends Biochem Sci"},{"key":"74","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1073\/pnas.85.14.5259","article-title":"Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines","volume":"85","author":"Rowley","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"75","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/nar\/18.4.993","article-title":"Polymerase chain reaction based assay to detect allelic loss in human DNA: loss of beta-interferon gene in chronic myelogenous leukemia","volume":"18","author":"Liu","year":"1990","journal-title":"Nucleic Acids Res"},{"key":"76","first-page":"7781","article-title":"Deletion of alpha-, beta-, and omega-interferon genes in malignant cells from children with acute lymphocytic leukemia","volume":"50","author":"Soderhall","year":"1990","journal-title":"Cancer Res"},{"key":"77","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood.V79.8.2076.2076","article-title":"Interferon system in primary acute lymphocytic leukemia cells with or without deletions of the alpha-\/beta-interferon genes","volume":"79","author":"Einhorn","year":"1992","journal-title":"Blood"},{"key":"78","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ijc.2910540507","article-title":"Deletions of the short arm of chromosome 9, including the interferon-alpha\/-beta genes, in acute lymphocytic leukemia. Studies on loss of heterozygosity, parental origin of deleted genes and prognosis","volume":"54","author":"Einhorn","year":"1993","journal-title":"Int J Cancer"},{"key":"79","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood.V80.3.744.744","article-title":"Correlation between interferon (IFN) alpha resistance and deletion of the IFN alpha\/beta genes in acute leukemia cell lines suggests selection against the IFN system","volume":"80","author":"Diaz","year":"1992","journal-title":"Blood"},{"key":"80","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.leu.2400553","article-title":"The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster","volume":"11","author":"Cross","year":"1997","journal-title":"Leukemia"},{"key":"81","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1046\/j.1365-2141.1997.2903110.x","article-title":"Alpha interferon gene deletions in post-transplant lymphoma","volume":"98","author":"Middleton","year":"1997","journal-title":"Br J Haematol"},{"key":"82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/(SICI)1097-0347(199803)20:2<113::AID-HED3>3.0.CO;2-5","article-title":"9p21 deletion correlates with recurrence in head and neck cancer","volume":"20","author":"Chaganti","year":"1998","journal-title":"Head Neck"},{"key":"83","first-page":"161","article-title":"Frequency of IFN beta 1 gene loss in 47 primary human gliomas","volume":"10","author":"Collins","year":"1993","journal-title":"Noshuyo Byori"},{"key":"84","first-page":"3674","article-title":"Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group","volume":"53","author":"Day","year":"1993","journal-title":"Cancer Res"},{"key":"85","first-page":"344","article-title":"Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia","volume":"54","author":"Lugo","year":"1994","journal-title":"Cancer Res"},{"key":"86","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1073\/pnas.89.21.10557","article-title":"Homozygous deletions within human chromosome band 9p21 in melanoma","volume":"89","author":"Lahti","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"87","first-page":"425","article-title":"Interferon system defects in malignant T-cells","volume":"8","author":"Einhorn","year":"1994","journal-title":"Leukemia"},{"key":"88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0165-4608(95)00157-3","article-title":"Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines","volume":"86","author":"Savarese","year":"1996","journal-title":"Cancer Genet Cytogenet"},{"key":"89","first-page":"1083","article-title":"Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy","volume":"56","author":"Savarese","year":"1996","journal-title":"Cancer Res"},{"key":"90","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/1541-7786.MCR-08-0344","article-title":"Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2","volume":"8","author":"Gamero","year":"2010","journal-title":"Mol Cancer Res"},{"key":"91","first-page":"e251","article-title":"Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma","volume":"19","author":"Bosserhoff","year":"2010","journal-title":"Exp Dermatol"},{"key":"92","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1006\/viro.2000.0584","article-title":"The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha","volume":"277","author":"McMillan","year":"2000","journal-title":"Virology"},{"key":"93","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1089\/jir.2009.0075","article-title":"Human papillomaviruses and the interferon response","volume":"29","author":"Laimins","year":"2009","journal-title":"J Interferon Cytokine Res"},{"key":"94","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Barber","year":"2009","journal-title":"Nature"},{"key":"95","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.celrep.2015.12.029","article-title":"Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis","volume":"14","author":"Barber","year":"2016","journal-title":"Cell Reports"},{"key":"96","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1158\/0008-5472.CAN-16-1404","article-title":"Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis","volume":"76","author":"Barber","year":"2016","journal-title":"Cancer Res"},{"key":"97","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","article-title":"Type I Interferon in Chronic Virus Infection and Cancer","volume":"38","author":"Brooks","year":"2017","journal-title":"Trends Immunol"},{"key":"98","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2017.01.004","article-title":"Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment","volume":"31","author":"Rustgi","year":"2017","journal-title":"Cancer Cell"},{"key":"99","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/hep.510290624","article-title":"Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines","volume":"29","author":"Kojiro","year":"1999","journal-title":"Hepatology"},{"key":"100","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1478-3231.2006.01321.x","article-title":"Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cellsand","volume":"26","author":"Kojiro","year":"2006","journal-title":"Liver Int"},{"key":"101","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/jhep.2001.21749","article-title":"Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases","volume":"33","author":"Rosewicz","year":"2001","journal-title":"Hepatology"},{"key":"102","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cyto.2005.08.011","article-title":"A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines","volume":"33","author":"Hayashi","year":"2006","journal-title":"Cytokine"},{"key":"103","first-page":"1821","article-title":"Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL\/Apo2L induction in melanoma cell lines","volume":"7","author":"Borden","year":"2001","journal-title":"Clin Cancer Res"},{"key":"104","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1089\/107999003772084860","article-title":"Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2","volume":"23","author":"Borden","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CMR.0b013e32835e7713","article-title":"Difference of interferon-\u03b1 and interferon-\u03b2 on melanoma growth and lymph node metastasis in mice","volume":"23","author":"Chung","year":"2013","journal-title":"Melanoma Res"},{"key":"106","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood.V98.7.2183","article-title":"Apo2L\/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma","volume":"98","author":"Almasan","year":"2001","journal-title":"Blood"},{"key":"107","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1006\/bbrc.2000.3872","article-title":"Genomic organization and transcriptional regulation of human Apo2\/TRAIL gene","volume":"278","author":"Almasan","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"108","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0002-9440(10)65373-4","article-title":"Interferon (IFN)-beta gene transfer into TS\/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response","volume":"154","author":"Ferrantini","year":"1999","journal-title":"Am J Pathol"},{"key":"109","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.2432664","article-title":"Angiogenic factors","volume":"235","author":"Klagsbrun","year":"1987","journal-title":"Science"},{"key":"110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"111","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(01)00622-2","article-title":"The seed and soil hypothesis: vascularisation and brain metastases","volume":"3","author":"Bucana","year":"2002","journal-title":"Lancet Oncol"},{"key":"112","first-page":"5155","article-title":"Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses","volume":"47","author":"Borden","year":"1987","journal-title":"Cancer Res"},{"key":"113","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jnci\/81.7.497","article-title":"Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice","volume":"81","author":"Gresser","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"114","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1073\/pnas.92.10.4562","article-title":"Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas","volume":"92","author":"Fidler","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"115","first-page":"808","article-title":"Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration","volume":"58","author":"Fidler","year":"1998","journal-title":"Cancer Res"},{"key":"116","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/sj.onc.1205341","article-title":"Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells","volume":"21","author":"Fidler","year":"2002","journal-title":"Oncogene"},{"key":"117","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/95.6.437","article-title":"Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis","volume":"95","author":"Rosewicz","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"118","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000080748","article-title":"Interferon-alpha: regulatory effects on cell cycle and angiogenesis","volume":"80","author":"von Marschall","year":"2004","journal-title":"Neuroendocrinology"},{"key":"119","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/jir.1996.16.577","article-title":"Interferon-beta prevents the upregulation of interleukin-8 expression in human melanoma cells","volume":"16","author":"Fidler","year":"1996","journal-title":"J Interferon Cytokine Res"},{"key":"120","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/jir.1998.18.897","article-title":"Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFN-alpha2b: increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8","volume":"18","author":"Dinarello","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"121","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1023\/A:1020923326441","article-title":"Evidence for the causal role of endogenous interferon-alpha\/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms","volume":"19","author":"Fidler","year":"2002","journal-title":"Clin Exp Metastasis"},{"key":"122","doi-asserted-by":"crossref","first-page":"23356","DOI":"10.1074\/jbc.M112.340505","article-title":"Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor \u03b1 (TNF\u03b1) and interferon \u03b1 (IFN\u03b1)","volume":"287","author":"Kao","year":"2012","journal-title":"J Biol Chem"},{"key":"123","first-page":"1590","article-title":"PML nuclear bodies are general targets for inflammation and cell proliferation","volume":"55","author":"Dejean","year":"1995","journal-title":"Cancer Res"},{"key":"124","first-page":"2565","article-title":"Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element","volume":"11","author":"Schindler","year":"1995","journal-title":"Oncogene"},{"key":"125","first-page":"e15","article-title":"Neurotrophin p75 receptor (p75NTR) promotes endothelial cell apoptosis and inhibits angiogenesis: implications for diabetes-induced impaired neovascularization in ischemic limb muscles","volume":"103","author":"Yoon","year":"2008","journal-title":"Circ Res"},{"key":"126","doi-asserted-by":"crossref","first-page":"9485","DOI":"10.1074\/jbc.M109.063362","article-title":"Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1","volume":"285","author":"Kao","year":"2010","journal-title":"J Biol Chem"},{"key":"127","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.4049\/jimmunol.1401109","article-title":"Therapeutic activity of high-dose intratumoral IFN-\u03b2 requires direct effect on the tumor vasculature","volume":"193","author":"Gajewski","year":"2014","journal-title":"J Immunol"},{"key":"128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1541-7786.MCR-06-0259","article-title":"Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculature","volume":"5","author":"Nathwani","year":"2007","journal-title":"Mol Cancer Res"},{"key":"129","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.cgt.7700333","article-title":"Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice","volume":"8","author":"Dong","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"130","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.4049\/jimmunol.167.9.5150","article-title":"Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha","volume":"167","author":"Benveniste","year":"2001","journal-title":"J Immunol"},{"key":"131","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1189\/jlb.71.1.89","article-title":"Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta","volume":"71","author":"Opdenakker","year":"2002","journal-title":"J Leukoc Biol"},{"key":"132","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1172\/JCI37223","article-title":"Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model","volume":"120","author":"Weiss","year":"2010","journal-title":"J Clin Invest"},{"key":"133","first-page":"1258","article-title":"Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis","volume":"8","author":"Dinney","year":"2002","journal-title":"Clin Cancer Res"},{"key":"134","first-page":"1253","article-title":"Potentiation of antiglioma effect with combined temozolomide and interferon-beta","volume":"16","author":"Hong","year":"2006","journal-title":"Oncol Rep"},{"key":"135","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/jir.2008.0030","article-title":"Identification of interferon-beta-stimulated genes that inhibit angiogenesis","volume":"28","author":"Lindner","year":"2008","journal-title":"J Interferon Cytokine Res"},{"key":"136","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/jir.2009.0103","article-title":"Effects of interferons \u03b1\/\u03b2 on the proliferation of human micro- and macrovascular endothelial cells","volume":"31","author":"van Eijck","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"137","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2011-06-359745","article-title":"Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis","volume":"118","author":"Fuchs","year":"2011","journal-title":"Blood"},{"key":"138","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0002-9440(10)65007-9","article-title":"Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach","volume":"156","author":"Noonan","year":"2000","journal-title":"Am J Pathol"},{"key":"139","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Schreiber","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"140","first-page":"578","article-title":"Danger signals - damaged-self recognition across the tree of life","volume":"5","author":"Land","year":"2014","journal-title":"Front Plant Sci"},{"key":"141","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0952-7915(02)00354-0","article-title":"Links between innate and adaptive immunity via type I interferon","volume":"14","author":"Tough","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"142","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.4049\/jimmunol.178.5.3126","article-title":"Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria","volume":"178","author":"Teti","year":"2007","journal-title":"J Immunol"},{"key":"143","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.imlet.2009.02.011","article-title":"Role of macrophages in tumour progression","volume":"123","author":"Kuttan","year":"2009","journal-title":"Immunol Lett"},{"key":"144","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Hertzog","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"145","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive Immune Resistance: How Cancer Protects from Immune Attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov"},{"key":"146","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"O'Garra","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"147","doi-asserted-by":"crossref","first-page":"e2446","DOI":"10.1038\/cddis.2016.350","article-title":"CD169(+) macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection","volume":"7","author":"Hardt","year":"2016","journal-title":"Cell Death Dis"},{"key":"148","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.it.2011.11.001","article-title":"CD169+ macrophages at the crossroads of antigen presentation","volume":"33","author":"Gordon","year":"2012","journal-title":"Trends Immunol"},{"key":"149","doi-asserted-by":"crossref","first-page":"36956","DOI":"10.1038\/srep36956","article-title":"PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients","volume":"6","author":"Yoon","year":"2016","journal-title":"Sci Rep"},{"key":"150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","article-title":"Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape","volume":"5","author":"Schreiber","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"151","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1084\/jem.178.5.1655","article-title":"Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells","volume":"178","author":"Heusser","year":"1993","journal-title":"J Exp Med"},{"key":"152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-2478(97)00091-6","article-title":"Type I interferons enhance production of IFN-gamma by NK cells","volume":"59","author":"Remington","year":"1997","journal-title":"Immunol Lett"},{"key":"153","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/toxins6061696","article-title":"Type I interferons as regulators of human antigen presenting cell functions","volume":"6","author":"Belardelli","year":"2014","journal-title":"Toxins (Basel)"},{"key":"154","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/blood-2009-07-234468","article-title":"LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells","volume":"115","author":"Belardelli","year":"2010","journal-title":"Blood"},{"key":"155","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/blood.V98.10.3022","article-title":"Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities","volume":"98","author":"Belardelli","year":"2001","journal-title":"Blood"},{"key":"156","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1172\/JCI60644","article-title":"The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice","volume":"122","author":"Reis e Sousa","year":"2012","journal-title":"J Clin Invest"},{"key":"157","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Fu","year":"2013","journal-title":"Nat Immunol"},{"key":"158","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","article-title":"Impaired IFN-\u03b1 production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression","volume":"72","author":"Bajard","year":"2012","journal-title":"Cancer Res"},{"key":"159","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI21583","article-title":"Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes","volume":"114","author":"Mellor","year":"2004","journal-title":"J Clin Invest"},{"key":"160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2016.07.004","article-title":"IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity","volume":"75","author":"Hugues","year":"2016","journal-title":"J Autoimmun"},{"key":"161","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/08820139.2012.676122","article-title":"Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity","volume":"41","author":"Egilmez","year":"2012","journal-title":"Immunol Invest"},{"key":"162","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","article-title":"Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer","volume":"63","author":"Muller","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"163","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Allison","year":"2013","journal-title":"J Exp Med"},{"key":"164","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/eji.200737184","article-title":"On watching the watchers: IDO and type I\/II IFN","volume":"37","author":"Puccetti","year":"2007","journal-title":"Eur J Immunol"},{"key":"165","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","article-title":"A novel transcription factor, T-bet, directs Th1 lineage commitment","volume":"100","author":"Glimcher","year":"2000","journal-title":"Cell"},{"key":"166","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","article-title":"Regulation of effector and memory T-cell functions by type I interferon","volume":"132","author":"Farrar","year":"2011","journal-title":"Immunology"},{"key":"167","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-004-0653-2","article-title":"Tumor antigen-specific T helper cells in cancer immunity and immunotherapy","volume":"54","author":"Disis","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"168","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/nri2438","article-title":"Immunotherapy of autoimmunity and cancer: the penalty for success","volume":"8","author":"Caspi","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"169","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Galon","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"170","first-page":"483","article-title":"Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response","volume":"4","author":"Gabriele","year":"2013","journal-title":"Front Immunol"},{"key":"171","first-page":"3208","article-title":"Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment","volume":"44","author":"Schlom","year":"1984","journal-title":"Cancer Res"},{"key":"172","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3171\/jns.2004.100.2.0310","article-title":"Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme","volume":"100","author":"Liau","year":"2004","journal-title":"J Neurosurg"},{"key":"173","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3747\/co.19.945","article-title":"Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time","volume":"19","author":"Giacomini","year":"2012","journal-title":"Curr Oncol"},{"key":"174","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","article-title":"Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy","volume":"77","author":"Sharma","year":"2017","journal-title":"Cancer Res"},{"key":"175","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1101\/sqb.2013.78.020255","article-title":"Immune surveillance of unhealthy cells by natural killer cells","volume":"78","author":"Raulet","year":"2013","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"176","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20112738","article-title":"Cancer immunoediting by the innate immune system in the absence of adaptive immunity","volume":"209","author":"Bui","year":"2012","journal-title":"J Exp Med"},{"key":"177","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.immuni.2014.05.003","article-title":"Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1","volume":"40","author":"Oxenius","year":"2014","journal-title":"Immunity"},{"key":"178","first-page":"235","article-title":"\"Natural Regulators\": NK Cells as Modulators of T Cell Immunity","volume":"7","author":"Degli-Esposti","year":"2016","journal-title":"Front Immunol"},{"key":"179","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2012.03.042","article-title":"Type I interferons maintain Foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice","volume":"143","author":"Raz","year":"2012","journal-title":"Gastroenterology"},{"key":"180","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.chom.2012.05.003","article-title":"Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection","volume":"11","author":"Colonna","year":"2012","journal-title":"Cell Host Microbe"},{"key":"181","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1235208","article-title":"Blockade of chronic type I interferon signaling to control persistent LCMV infection","volume":"340","author":"Brooks","year":"2013","journal-title":"Science"},{"key":"182","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Oldstone","year":"2013","journal-title":"Science"},{"key":"183","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1126\/science.1237568","article-title":"Immunology An interferon paradox","volume":"340","author":"Wherry","year":"2013","journal-title":"Science"},{"key":"184","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Schuchter","year":"2016","journal-title":"Cell"},{"key":"185","article-title":"Gene Therapy for Melanoma: Progress and Perspectives. Recent Advances in the Biology, Therapy and Management of Melanoma","author":"Costanzi-Strauss","year":"2013","journal-title":"InTech"},{"key":"186","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11912-014-0409-x","article-title":"New options for the adjuvant treatment of cutaneous melanoma?","volume":"16","author":"Flaherty","year":"2014","journal-title":"Curr Oncol Rep"},{"key":"187","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Blum","year":"1996","journal-title":"J Clin Oncol"},{"key":"188","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Rao","year":"2001","journal-title":"J Clin Oncol"},{"key":"189","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1517\/14712598.2012.694421","article-title":"Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma","volume":"12","author":"Hauschild","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2009.10.004","article-title":"Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma","volume":"46","author":"Hauschild","year":"2010","journal-title":"Eur J Cancer"},{"key":"191","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000336490","article-title":"Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study","volume":"82","author":"Shimizu","year":"2012","journal-title":"Oncology"},{"key":"192","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2014.11.008","article-title":"The use of interferon in melanoma patients: a systematic review","volume":"26","author":"Ascierto","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"193","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","article-title":"Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses","volume":"24","author":"Kirkwood","year":"2006","journal-title":"J Clin Oncol"},{"key":"194","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/jir.2010.0054","article-title":"Gene regulatory and clinical effects of interferon beta in patients with metastatic melanoma: a phase II trial","volume":"31","author":"Triozzi","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1540-9740.2006.05678.x","article-title":"Phase 2 trial of the continuous IV administration of interferon-beta in patients with disseminated malignant melanoma","volume":"5","author":"Fierlbeck","year":"2006","journal-title":"Skinmed"},{"key":"196","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.2015.63.3776","article-title":"Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy","volume":"34","author":"Davidson","year":"2016","journal-title":"J Clin Oncol"},{"key":"197","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2015.11.014","article-title":"Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity","volume":"55","author":"Group","year":"2016","journal-title":"Eur J Cancer"},{"key":"198","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2014.59.6932","article-title":"Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial","volume":"33","author":"Holzle","year":"2015","journal-title":"J Clin Oncol"},{"key":"199","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.hoc.2014.02.004","article-title":"Melanoma adjuvant therapy","volume":"28","author":"Thalanayar","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"200","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MJT.0b013e31829e883d","article-title":"Who benefits most from adjuvant interferon treatment for melanoma?","volume":"22","author":"Espinosa","year":"2015","journal-title":"Am J Ther"},{"key":"201","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/030089161209800202","article-title":"Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors","volume":"98","author":"Feliciani","year":"2012","journal-title":"Tumori"},{"key":"202","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1479-5876-8-20","article-title":"A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899","volume":"8","author":"Wilding","year":"2010","journal-title":"J Transl Med"},{"key":"203","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Cassinat","year":"2016","journal-title":"Leukemia"},{"key":"204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08923973.2014.971963","article-title":"Cancer vaccine adjuvants\u2014recent clinical progress and future perspectives","volume":"37","author":"Hruby","year":"2015","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"205","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","article-title":"Twelve immunotherapy drugs that could cure cancers","volume":"222","author":"Cheever","year":"2008","journal-title":"Immunol Rev"},{"key":"206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12307-009-0022-y","article-title":"Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment","volume":"2","author":"Hoon","year":"2009","journal-title":"Cancer Microenviron"},{"key":"207","doi-asserted-by":"crossref","first-page":"21502","DOI":"10.1074\/jbc.M301476200","article-title":"Species-specific regulation of Toll-like receptor 3 genes in men and mice","volume":"278","author":"Rehli","year":"2003","journal-title":"J Biol Chem"},{"key":"208","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.4049\/jimmunol.164.11.5998","article-title":"Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells","volume":"164","author":"Mantovani","year":"2000","journal-title":"J Immunol"},{"key":"209","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/infdis\/132.4.434","article-title":"A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates","volume":"132","author":"Rice","year":"1975","journal-title":"J Infect Dis"},{"key":"210","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/imm.12143","article-title":"Toll-like receptor 3 in viral pathogenesis: friend or foe?","volume":"140","author":"Navas-Martin","year":"2013","journal-title":"Immunology"},{"key":"211","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cellimm.2010.05.008","article-title":"Double stranded RNA- relative to other TLR ligand-activated dendritic cells induce extremely polarized human Th1 responses","volume":"264","author":"Lee","year":"2010","journal-title":"Cell Immunol"},{"key":"212","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.vaccine.2008.11.013","article-title":"The TLR3 agonist poly(I: C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na\u03bfve recipient mice","volume":"27","author":"Cole","year":"2009","journal-title":"Vaccine"},{"key":"213","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s13277-013-0693-3","article-title":"Polyinosinic-cytidylic acid as an adjuvant on natural killer- and dendritic cell-mediated antitumor activities","volume":"34","author":"Qiu","year":"2013","journal-title":"Tumour Biol"},{"key":"214","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1084\/jem.20091181","article-title":"Distinct and complementary functions of MDA5 and TLR3 in poly(I: C)-mediated activation of mouse NK cells","volume":"206","author":"Colonna","year":"2009","journal-title":"J Exp Med"},{"key":"215","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.4161\/cbt.10.12.13450","article-title":"Anticancer function of polyinosinic-polycytidylic acid","volume":"10","author":"Xu","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"216","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.20111171","article-title":"Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans","volume":"208","author":"Nelkenbaum","year":"2011","journal-title":"J Exp Med"},{"key":"217","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1078-0432.CCR-10-2563","article-title":"Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy","volume":"17","author":"Liau","year":"2011","journal-title":"Clin Cancer Res"},{"key":"218","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1158\/1078-0432.CCR-12-2189","article-title":"Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients","volume":"18","author":"Tew","year":"2012","journal-title":"Clin Cancer Res"},{"key":"219","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clim.2015.09.003","article-title":"Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I: C","volume":"161","author":"McKee","year":"2015","journal-title":"Clin Immunol"},{"key":"220","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/BF01709367","article-title":"Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection","volume":"15","author":"Carter","year":"1996","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"221","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.vaccine.2008.10.024","article-title":"A clinical grade poly I: C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients","volume":"27","author":"Adams","year":"2009","journal-title":"Vaccine"},{"key":"222","first-page":"a016253","article-title":"Emerging principles governing signal transduction by pattern-recognition receptors","volume":"7","author":"Barton","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"223","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature09121","article-title":"Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR\/IL-1R signalling","volume":"465","author":"Wu","year":"2010","journal-title":"Nature"},{"key":"224","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","article-title":"TLR signaling","volume":"13","author":"Akira","year":"2006","journal-title":"Cell Death Differ"},{"key":"225","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.immuni.2015.10.008","article-title":"Mechanisms of Toll-like Receptor 4 Endocytosis Reveal a Common Immune-Evasion Strategy Used by Pathogenic and Commensal Bacteria","volume":"43","author":"Kagan","year":"2015","journal-title":"Immunity"},{"key":"226","first-page":"381","article-title":"Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy","volume":"56","author":"Taniwaki","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"227","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14653240701589221","article-title":"Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer","volume":"9","author":"Felzmann","year":"2007","journal-title":"Cytotherapy"},{"key":"228","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/0008-5472.CAN-06-4038","article-title":"Targeting HER-2\/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion","volume":"67","author":"Vonderheide","year":"2007","journal-title":"Cancer Res"},{"key":"229","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","article-title":"A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside","volume":"19","author":"Czerniecki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"230","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-07-4899","article-title":"Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor","volume":"14","author":"Chain","year":"2008","journal-title":"Clin Cancer Res"},{"key":"231","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.1078231","article-title":"Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells","volume":"299","author":"Medzhitov","year":"2003","journal-title":"Science"},{"key":"232","doi-asserted-by":"crossref","first-page":"e74698","DOI":"10.1371\/journal.pone.0074698","article-title":"Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine","volume":"8","author":"Czerniecki","year":"2013","journal-title":"PLoS One"},{"key":"233","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Limson","year":"2009","journal-title":"Lancet"},{"key":"234","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.4049\/jimmunol.180.4.2117","article-title":"TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages","volume":"180","author":"Williams","year":"2008","journal-title":"J Immunol"},{"key":"235","first-page":"96","article-title":"[Toll-like receptor 8: the awkward TLR]. [Article in French]","volume":"28","author":"Demaria","year":"2012","journal-title":"Med Sci (Paris)"},{"key":"236","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.jaad.2011.11.933","article-title":"A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes","volume":"66","author":"Guill\u00e9n","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"237","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ni1303","article-title":"Innate immune recognition of viral infection","volume":"7","author":"Akira","year":"2006","journal-title":"Nat Immunol"},{"key":"238","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","article-title":"Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7","volume":"11","author":"Hartmann","year":"2005","journal-title":"Nat Med"},{"key":"239","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Akira","year":"2010","journal-title":"Nat Immunol"},{"key":"240","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0198-8859(02)00748-6","article-title":"Human and mouse plasmacytoid dendritic cells","volume":"63","author":"Wagner","year":"2002","journal-title":"Hum Immunol"},{"key":"241","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Akira","year":"2002","journal-title":"Nat Immunol"},{"key":"242","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.humimm.2007.01.018","article-title":"Early activation markers of human peripheral dendritic cells","volume":"68","author":"Eriksson","year":"2007","journal-title":"Hum Immunol"},{"key":"243","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1172\/JCI61034","article-title":"Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells","volume":"122","author":"Sibilia","year":"2012","journal-title":"J Clin Invest"},{"key":"244","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.4049\/jimmunol.1102437","article-title":"TRAIL(+) human plasmacytoid dendritic cells kill tumor cells: mechanisms of imiquimod- and IFN-\u03b1-mediated antitumor reactivity","volume":"188","author":"Stingl","year":"2012","journal-title":"J Immunol"},{"key":"245","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0190-9622(99)70261-6","article-title":"Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream","volume":"41","author":"Owens","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"246","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-4632.2007.03200.x","article-title":"Successful treatment of perianal Bowen's disease with imiquimod","volume":"46","author":"Sinclair","year":"2007","journal-title":"Int J Dermatol"},{"key":"247","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jnci\/dji207","article-title":"Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment","volume":"97","author":"Gilliet","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"248","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.4049\/jimmunol.173.5.3051","article-title":"Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod","volume":"173","author":"Sibilia","year":"2004","journal-title":"J Immunol"},{"key":"249","first-page":"103298","article-title":"Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model","volume":"2012","author":"Scherr","year":"2012","journal-title":"J Oncol"},{"key":"250","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1158\/1078-0432.CCR-05-0616","article-title":"Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment","volume":"11","author":"van der Burg","year":"2005","journal-title":"Clin Cancer Res"},{"key":"251","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1600-0714.2012.01158.x","article-title":"Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis","volume":"41","author":"Yoon","year":"2012","journal-title":"J Oral Pathol Med"},{"key":"252","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bbrc.2009.06.046","article-title":"Autophagy-mediated anti-tumoral activity of imiquimod in Caco-2 cells","volume":"386","author":"Chung","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"253","doi-asserted-by":"publisher","first-page":"24932","DOI":"10.18632\/oncotarget.15326","article-title":"The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"254","first-page":"708","article-title":"Imiquimod as an antiangiogenic agent","volume":"4","author":"Zhai","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00431-014-2404-5","article-title":"Educational paper: therapy of infantile haemangioma\u2014history and current state (part II)","volume":"174","author":"Oranje","year":"2015","journal-title":"Eur J Pediatr"},{"key":"256","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jaad.2012.04.018","article-title":"Treatments for classic Kaposi sarcoma: a systematic review of the literature","volume":"68","author":"Dupin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"257","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.0007-0963.2004.05898.x","article-title":"andmodulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases","volume":"150","author":"Bignon","year":"2004","journal-title":"Br J Dermatol"},{"key":"258","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Akira","year":"2000","journal-title":"Nature"},{"key":"259","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI31414","article-title":"Development of TLR9 agonists for cancer therapy","volume":"117","author":"Krieg","year":"2007","journal-title":"J Clin Invest"},{"key":"260","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.1073\/pnas.96.16.9305","article-title":"CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells","volume":"96","author":"Krieg","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"261","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U","article-title":"Identification of CpG oligonucleotide sequences with high induction of IFN-alpha\/beta in plasmacytoid dendritic cells","volume":"31","author":"Hartmann","year":"2001","journal-title":"Eur J Immunol"},{"key":"262","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.addr.2007.12.004","article-title":"TLR9 as a key receptor for the recognition of DNA","volume":"60","author":"Akira","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"263","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.157.5.1840","article-title":"Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.","volume":"157","author":"Krieg","year":"1996","journal-title":"J Immunol"},{"key":"264","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Ganne","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"265","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/ijc.26297","article-title":"Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells","volume":"130","author":"Speiser","year":"2012","journal-title":"Int J Cancer"},{"key":"266","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/eji.201142361","article-title":"Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8T-cell responses in melanoma patients","volume":"42","author":"Speiser","year":"2012","journal-title":"Eur J Immunol"},{"key":"267","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.cell.2007.09.008","article-title":"Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"268","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.4049\/jimmunol.170.8.4134","article-title":"Definition of structural prerequisites for lipoteichoic acid-inducible cytokine induction by synthetic derivatives","volume":"170","author":"Hartung","year":"2003","journal-title":"J Immunol"},{"key":"269","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/ni774","article-title":"TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha\/beta-dependent gene expression in macrophages","volume":"3","author":"Vogel","year":"2002","journal-title":"Nat Immunol"},{"key":"270","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.4049\/jimmunol.1002320","article-title":"TLR1\/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells","volume":"186","author":"Chu","year":"2011","journal-title":"J Immunol"},{"key":"271","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clim.2014.06.004","article-title":"Systemic injection of TLR1\/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice","volume":"154","author":"Chu","year":"2014","journal-title":"Clin Immunol"},{"key":"272","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1158\/1078-0432.CCR-13-2522","article-title":"Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells","volume":"20","author":"Gasser","year":"2014","journal-title":"Clin Cancer Res"},{"key":"273","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/eji.201444874","article-title":"Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia","volume":"45","author":"Schultz","year":"2015","journal-title":"Eur J Immunol"},{"key":"274","doi-asserted-by":"crossref","first-page":"e10250","DOI":"10.1371\/journal.pone.0010250","article-title":"Murine toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments","volume":"5","author":"Gekara","year":"2010","journal-title":"PLoS One"},{"key":"275","doi-asserted-by":"crossref","first-page":"6090","DOI":"10.4049\/jimmunol.1401605","article-title":"TRAM is required for TLR2 endosomal signaling to type I IFN induction","volume":"193","author":"Bowie","year":"2014","journal-title":"J Immunol"},{"key":"276","first-page":"158","article-title":"The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells","volume":"8","author":"Wu","year":"2017","journal-title":"Front Immunol"},{"key":"277","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1126\/science.1244040","article-title":"Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects","volume":"341","author":"Chen","year":"2013","journal-title":"Science"},{"key":"278","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Chen","year":"2013","journal-title":"Science"},{"key":"279","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.1229963","article-title":"Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA","volume":"339","author":"Chen","year":"2013","journal-title":"Science"},{"key":"280","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature12306","article-title":"cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING","volume":"498","author":"Hornung","year":"2013","journal-title":"Nature"},{"key":"281","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00109-016-1423-2","article-title":"The role of cGAS in innate immunity and beyond","volume":"94","author":"Gulen","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"282","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Gajewski","year":"2014","journal-title":"Immunity"},{"key":"283","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Speiser","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"284","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.1621363114","article-title":"cGAS is essential for the antitumor effect of immune checkpoint blockade","volume":"114","author":"Chen","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"285","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-15-1456","article-title":"STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation","volume":"76","author":"Mellor","year":"2016","journal-title":"Cancer Res"},{"key":"286","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature18268","article-title":"Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer","volume":"533","author":"Massagu\u00e9","year":"2016","journal-title":"Nature"},{"key":"287","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secretally: immunostimulation by anticancer drugs","volume":"11","author":"Kroemer","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"288","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/cas.12695","article-title":"Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy","volume":"106","author":"Tamada","year":"2015","journal-title":"Cancer Sci"},{"key":"289","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Pichard","year":"2005","journal-title":"J Exp Med"},{"key":"290","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"van Endert","year":"2007","journal-title":"Nat Med"},{"key":"291","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Kroemer","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"292","doi-asserted-by":"crossref","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Brough","year":"2014","journal-title":"Oncoimmunology"},{"key":"293","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Aymeric","year":"2014","journal-title":"Nat Med"},{"key":"294","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Auh","year":"2011","journal-title":"Cancer Res"},{"key":"295","first-page":"E313","article-title":"Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death","volume":"136","author":"Van Gool","year":"2015","journal-title":"OncoImmunology"},{"key":"296","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Allison","year":"2014","journal-title":"Sci Transl Med"},{"key":"297","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00262-012-1305-6","article-title":"Innate immune sensing of cancer: clues from an identified role for type I IFNs","volume":"61","author":"Woo","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"298","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2011.01051.x","article-title":"Cytoplasmic DNA innate immune pathways","volume":"243","author":"Barber","year":"2011","journal-title":"Immunol Rev"},{"key":"299","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1158\/1078-0432.CCR-07-0892","article-title":"Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment","volume":"13","author":"Gajewski","year":"2007","journal-title":"Clin Cancer Res"},{"key":"300","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nm.2652","article-title":"Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system","volume":"18","author":"de Visser","year":"2012","journal-title":"Nat Med"},{"key":"301","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy","volume":"44","author":"Iwamoto","year":"2016","journal-title":"Immunity"},{"key":"302","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/978-1-60761-588-0_27","article-title":"Evaluation of targets for ovarian cancer gene silencing therapy:andapproaches","volume":"623","author":"Tchernitsa","year":"2010","journal-title":"Methods Mol Biol"},{"key":"303","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/hed.20529","article-title":"Restoration of wild-type p53 function in human cancer: relevance for tumor therapy","volume":"29","author":"Sacchi","year":"2007","journal-title":"Head Neck"},{"key":"304","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2141.2002.03365.x","article-title":"Immunomodulatory gene therapy for haematological malignancies","volume":"117","author":"Schmidt-Wolf","year":"2002","journal-title":"Br J Haematol"},{"key":"305","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cytogfr.2007.06.020","article-title":"Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma","volume":"18","author":"Kirkwood","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"306","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/cgt.2012.27","article-title":"Interferon-\u03b2 lipofection I. Increased efficacy of chemotherapeutic drugs on human tumor cells derived monolayers and spheroids","volume":"19","author":"Finocchiaro","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"307","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.biopha.2016.06.038","article-title":"The combination of bleomycin with suicide or interferon-\u03b2 gene transfer is able to efficiently eliminate human melanoma tumor initiating cells","volume":"83","author":"Finocchiaro","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"308","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biopha.2015.04.002","article-title":"Interferon-\u03b2 gene transfer induces a strong cytotoxic bystander effect on melanoma cells","volume":"72","author":"Glikin","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"309","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cyto.2015.11.012","article-title":"Interferon-\u03b2 gene transfer inhibits melanoma cells adhesion and migration","volume":"89","author":"Glikin","year":"2017","journal-title":"Cytokine"},{"key":"310","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jgm.1160","article-title":"A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy","volume":"10","author":"Yoshida","year":"2008","journal-title":"J Gene Med"},{"key":"311","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12017-009-8059-0","article-title":"AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models","volume":"11","author":"Dyer","year":"2009","journal-title":"Neuromolecular Med"},{"key":"312","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1349-7006.2007.00408.x","article-title":"Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster","volume":"98","author":"Aoki","year":"2007","journal-title":"Cancer Sci"},{"key":"313","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bjc.6602713","article-title":"Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer","volume":"93","author":"Aoki","year":"2005","journal-title":"Br J Cancer"},{"key":"314","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/jgm.602","article-title":"Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer","volume":"6","author":"Aoki","year":"2004","journal-title":"J Gene Med"},{"key":"315","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/hum.2005.16.957","article-title":"Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition","volume":"16","author":"Amadori","year":"2005","journal-title":"Hum Gene Ther"},{"key":"316","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cas.12332","article-title":"Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-\u03b1 gene therapy for pancreatic cancer","volume":"105","author":"Aoki","year":"2014","journal-title":"Cancer Sci"},{"key":"317","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/j.1349-7006.2010.01578.x","article-title":"Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer","volume":"101","author":"Aoki","year":"2010","journal-title":"Cancer Sci"},{"key":"318","doi-asserted-by":"crossref","first-page":"155","DOI":"10.15252\/emmm.201505395","article-title":"IFN\u03b1 gene\/cell therapy curbs colorectal cancer colonization of the liver by acting on the hepatic microenvironment","volume":"8","author":"Guidotti","year":"2016","journal-title":"EMBO Mol Med"},{"key":"319","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2008.09.004","article-title":"Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis","volume":"14","author":"Galli","year":"2008","journal-title":"Cancer Cell"},{"key":"320","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Zhang","year":"2013","journal-title":"J Urol"},{"key":"321","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/gt.2008.101","article-title":"Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model","volume":"15","author":"Ponnazhagan","year":"2008","journal-title":"Gene Ther"},{"key":"322","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cyto.2014.10.029","article-title":"Suppression of proliferation, tumorigenicity and metastasis of lung cancer cells after their transduction by interferon-beta gene in baculovirus vector","volume":"71","author":"Vorontsova","year":"2015","journal-title":"Cytokine"},{"key":"323","first-page":"6201","article-title":"Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity","volume":"61","author":"Albelda","year":"2001","journal-title":"Cancer Res"},{"key":"324","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1878-0261.12020","article-title":"Intracranial AAV-IFN-\u03b2 gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model","volume":"11","author":"Sena-Esteves","year":"2017","journal-title":"Mol Oncol"},{"key":"325","first-page":"1508","article-title":"Systemic AAV9-IFN\u03b2 gene delivery treats highly invasive glioblastoma","volume":"18","author":"Sena-Esteves","year":"2016","journal-title":"Neuro Oncol"},{"key":"326","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.1158\/0008-5472.CAN-05-0920","article-title":"Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung","volume":"65","author":"Albelda","year":"2005","journal-title":"Cancer Res"},{"key":"327","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1158\/1078-0432.CCR-05-0502","article-title":"Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models","volume":"11","author":"Davidoff","year":"2005","journal-title":"Clin Cancer Res"},{"key":"328","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jtcvs.2003.08.034","article-title":"Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma","volume":"127","author":"Albelda","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"329","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.surg.2003.08.015","article-title":"Interferon-beta gene therapy improves survival in an immunocompetent mouse model of carcinomatosis","volume":"135","author":"Fraker","year":"2004","journal-title":"Surgery"},{"key":"330","doi-asserted-by":"publisher","first-page":"33165","DOI":"10.18632\/oncotarget","article-title":"Vesicular stomatitis virus expressing interferon-beta is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Federspiel","year":"2015","journal-title":"Oncotarget"},{"key":"331","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/hed.23502","article-title":"Preclinical safety and activity of recombinant VSV-IFN-beta in an immunocompetent model of squamous cell carcinoma of the head and neck","volume":"36","author":"Merchan","year":"2014","journal-title":"Head Neck"},{"key":"332","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/hum.2009.088","article-title":"Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy","volume":"21","author":"Russell","year":"2010","journal-title":"Hum Gene Ther"},{"key":"333","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/jjco\/hyn114","article-title":"A pilot study of human interferon beta gene therapy for patients with advanced melanoma bytransduction using cationic liposomes","volume":"38","author":"Yoshida","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"334","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/ncponc0658","article-title":"Interferon beta adenoviral gene therapy in a patient with ovarian cancer","volume":"3","author":"Vonderheide","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"335","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Litzky","year":"2010","journal-title":"Mol Ther"},{"key":"336","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/sj.mt.6300396","article-title":"A phase I trial of Ad.hIFN-beta gene therapy for glioma","volume":"16","author":"Kirn","year":"2008","journal-title":"Mol Ther"},{"key":"337","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI21926","article-title":"Progress on new vaccine strategies for the immunotherapy and prevention of cancer","volume":"113","author":"Morris","year":"2004","journal-title":"J Clin Invest"},{"key":"338","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/sj.gt.3302300","article-title":"Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response","volume":"11","author":"Okada","year":"2004","journal-title":"Gene Ther"},{"key":"339","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.4049\/jimmunol.175.4.2730","article-title":"Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways","volume":"175","author":"Pollack","year":"2005","journal-title":"J Immunol"},{"key":"340","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1089\/hum.2009.145","article-title":"Dendritic cell-based cancer gene therapy","volume":"20","author":"Van Tendeloo","year":"2009","journal-title":"Hum Gene Ther"},{"key":"341","first-page":"139","article-title":"Adenovirus-mediated gene delivery to dendritic cells","volume":"246","author":"Curiel","year":"2004","journal-title":"Methods Mol Biol"},{"key":"342","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.gt.3301406","article-title":"Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression","volume":"8","author":"Vuk-Pavlovic","year":"2001","journal-title":"Gene Ther"},{"key":"343","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1128\/JVI.01530-06","article-title":"Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy","volume":"81","author":"Kremer","year":"2007","journal-title":"J Virol"},{"key":"344","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.leu.2402511","article-title":"mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation","volume":"16","author":"Berneman","year":"2002","journal-title":"Leukemia"},{"key":"345","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/79463","article-title":"Efficient gene transfer to airway epithelium using recombinant Sendai virus","volume":"18","author":"Nagai","year":"2000","journal-title":"Nat Biotechnol"},{"key":"346","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.2741\/2809","article-title":"Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen","volume":"13","author":"Hasegawa","year":"2008","journal-title":"Front Biosci"},{"key":"347","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/imm.12509","article-title":"Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells","volume":"146","author":"Schmidt","year":"2015","journal-title":"Immunology"},{"key":"348","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.virol.2007.11.015","article-title":"Development of an adenoviral vector with robust expression driven by p53","volume":"371","author":"Strauss","year":"2008","journal-title":"Virology"},{"key":"349","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/sj.onc.1206461","article-title":"The INK4a\/ARF locus and melanoma","volume":"22","author":"Chin","year":"2003","journal-title":"Oncogene"},{"key":"350","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1073\/pnas.95.14.8292","article-title":"Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2","volume":"95","author":"Sherr","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"351","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-07-2069","article-title":"p53-Dependent and p53-independent activation of autophagy by ARF","volume":"68","author":"Gu","year":"2008","journal-title":"Cancer Res"},{"key":"352","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/ijc.25511","article-title":"The ARF tumor suppressor: structure, functions and status in cancer","volume":"127","author":"Gazzeri","year":"2010","journal-title":"Int J Cancer"},{"key":"353","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01850","article-title":"Integration of interferon-alpha\/beta signalling to p53 responses in tumour suppression and antiviral defence","volume":"424","author":"Taniguchi","year":"2003","journal-title":"Nature"},{"key":"354","doi-asserted-by":"crossref","first-page":"32275","DOI":"10.1074\/jbc.M313830200","article-title":"Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines","volume":"279","author":"Colamonici","year":"2004","journal-title":"J Biol Chem"},{"key":"355","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/humu.10179","article-title":"TP53 mutations in human skin cancers","volume":"21","author":"Sarasin","year":"2003","journal-title":"Hum Mutat"},{"key":"356","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/cgt.2013.23","article-title":"Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanomaand","volume":"20","author":"Strauss","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"357","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00262-016-1807-8","article-title":"Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy","volume":"65","author":"Strauss","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"358","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.tranon.2016.09.011","article-title":"Intratumoral Immunization by p19Arf and Interferon-\u03b2 Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma","volume":"9","author":"Strauss","year":"2016","journal-title":"Transl Oncol"},{"key":"359","doi-asserted-by":"crossref","first-page":"17017","DOI":"10.1038\/cddiscovery.2017.17","article-title":"Reestablishment of p53\/Arf and interferon-\u03b2 pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death","volume":"3","author":"Strauss","year":"2017","journal-title":"Cell Death Dis"},{"key":"360","doi-asserted-by":"crossref","first-page":"e1149673","DOI":"10.1080\/2162402X.2016.1149673","article-title":"Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy","volume":"5","author":"Kroemer","year":"2016","journal-title":"OncoImmunology"},{"key":"361","doi-asserted-by":"crossref","first-page":"328ra27","DOI":"10.1126\/scitranslmed.aae0105","article-title":"Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma","volume":"8","author":"Agostinis","year":"2016","journal-title":"Sci Transl Med"},{"key":"362","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.4049\/jimmunol.1501044","article-title":"In Vivo Visualizing the IFN-\u03b2 Response Required for Tumor Growth Control in a Therapeutic Model of Polyadenylic-Polyuridylic Acid Administration","volume":"196","author":"Maccioni","year":"2016","journal-title":"J Immunol"},{"key":"363","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.4049\/jimmunol.0804277","article-title":"Novel reporter mouse reveals constitutive and inflammatory expression of IFN-beta","volume":"183","author":"Weiss","year":"2009","journal-title":"J Immunol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:39:00Z","timestamp":1719329940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":363,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2017,9,19]]}},"alternative-id":["19531","29050360"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19531","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,25]]}}}